Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):247-253
Date
12/11/2021Pubmed ID
34889401Pubmed Central ID
PMC8791097DOI
10.1182/hematology.2021000256Scopus ID
2-s2.0-85122445074 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
The approval of brentuximab vedotin (BV) and checkpoint inhibitors (CPI) has revolutionized the management of relapsed/refractory classical Hodgkin lymphoma (cHL) patients. In recent years these agents have rapidly moved to earlier lines of therapy, including post-autologous hematopoietic cell transplant (auto-HCT) consolidation, pre-HCT salvage, and the frontline treatment setting. This shift in practice means that double-refractory (refractory to both BV and CPI) cHL is becoming an increasingly common clinical problem. In patients who are not eligible for clinical trials, conventional cytotoxic and targeted therapies (off label) may be a potential option. In patients who are transplant eligible, early referral to allogeneic HCT should be considered given the significant improvement in transplant outcomes in the contemporary era. Cellular therapy options including CD30.chimeric antigen receptor T cells, Epstein-Barr virus-directed cytotoxic T cells, and CD16A/30 bispecific natural killer cell engagers appear promising and are currently in clinical trials.
Author List
Epperla N, Hamadani MAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntineoplastic Agents, Immunological
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Humans
Male
Neoplasm Recurrence, Local
Transplantation, Autologous
